“‘Pharma bro’ Martin Shkreli released from prison early”
Convicted “Pharma bro” Martin Shkreli was released from federal prison Wednesday, less than five years into a seven-year sentence, his attorney said.
“I am pleased to report that Martin Shkreli has been released from Allenwood prison and transferred to a BOP halfway house after completing all programs that allowed for his prison sentence to be shortened,” his attorney, Ben Brafman, said in a statement.
Brafman added that he had advised Shkreli to make no further statements while in the halfway house.
A spokesperson at FCI Allenwood — the minimum-security federal prison in Pennsylvania where Shkreli was being held — confirmed the release, and told The Post that Shkreli was projected to be released from a New York State halfway house in September.
Shkreli was convicted in 2017 of defrauding investors in a series of his hedge funds.
By then, he was already a renowned and reviled figure for jacking up the price of anti-parasitic drug Daraprim as CEO of Turing Pharmaceuticals in 2015.
The drug, which is used to treat infections that occur in patients suffering from cancer and AIDS, skyrocketed in price overnight.
A single pill went from $13.50 to $750 — a staggering increase of 5,500 percent.
At the time, Shkreli defended the price hike as capitalism at work.
Shkreli has since been barred from ever working in the pharmaceutical industry again. He has also been ordered to return the $64 million in profits the price gouging made his firm.
Despite his notoriety, Shkreli’s release was met with praise from some corners of the internet.
A man named Edmund Sullivan shared a photo on Twitter announcing Shkreli’s freedom.
“Picked up this guy hitchhiking. Says he’s famous,” he wrote, along with an image of the ex-con in the back seat of a car.
If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.
For forums sites go to Forum.BuradaBiliyorum.Com
If you want to read more News articles, you can visit our News category.